Merck
HomeServicesProduct ServicesEmprove® ProgramEmprove® Dossiers for Cell Culture Media in Upstream Processes

Emprove® Dossiers for Cell Culture Media in Upstream Processes

Illustration of scientist focused on quality of final drug product, supported by Emprove® CCM portfolio

Cell culture media (CCM) drive the productivity of upstream processes and help ensure critical quality attributes of the final drug product. Because of this critical role in manufacturing, along with increased regulatory focus on raw materials, it is recommended that media be included in drug product risk assessments.1,2

To ease the burden of collecting the extensive information needed for a thorough assessment, Cellvento® CHO cell culture media are included in our Emprove® Program.

Subscribe to Emprove® Suite

Dossiers that support upstream productivity, risk assessment, and product quality

As part of the Emprove® Program, cell culture media in our Emprove® CCM portfolio include comprehensive dossiers that facilitate your process optimization, risk assessment, and quality efforts.

Target Emprove® Dossier Availability for Cellvento® Media

Emprove® Suite: 24/7 online access to all our dossiers

Unlock all the benefits of the Emprove® Program by subscribing to our Emprove® Suite. Available exclusively for subscribers, all dossiers of the entire Emprove® portfolio can be accessed at your convenience.

  • Subscriptions of one or two years
  • 24/7 online access
  • Constantly updated
  • Optimized searches

Related Product Resources

Tool: Risk Mitigation and Quality Requirements: Support for Bioprocesses
Brochure: Ease your regulatory efforts with Cellvento® CHO media

RELATED SERVICES
Emprove® Program
Confidently speed your way through the regulatory maze and fast track your new drug to market with the Emprove® Program. High-quality products, comprehensive documentation, and superior customer support facilitate your efforts in qualification, risk assessment, and process optimization.
Emprove® Chemicals
To simplify raw material selection while satisfying regulatory requirements, our Emprove® Chemicals portfolio contains over 400 pharmaceutical raw materials offering the comprehensive, up-to-date documentation you need to navigate regulatory challenges, manage risks, and improve processes.
Emprove® Chromatography
The Emprove® Chromatography portfolio streamlines resin selection and qualification for biopharmaceutical manufacturers, built to address process-specific needs at steps from early to late downstream.
Emprove® Filters and Single-Use Components
Answering industry-wide demand for increased transparency, our Emprove® Filter and Single-use Components portfolio helps biopharmaceutical manufacturers advance their product development with confidence.

Related Videos

Slide 1 of 3
  • Emprove<sup>®</sup> Categories
    Emprove® Categories
    The Emprove® Program contains over 400 raw and starting materials as well as 20 filter and single-use product families.
  • Emprove<sup>®</sup> Dossiers
    Emprove® Dossiers
    Emprove® Dossiers provide comprehensive, up-to-date documentation to help you navigate regulatory challenges, manage risks, and improve your manufacturing processes.
  • Emprove<sup>®</sup> Learning
    Emprove® Learning
    Each product portfolio is supported with Emprove® Dossiers which provide comprehensive, up-to-date documentation to help you navigate regulatory challenges, manage risks, and improve your manufacturing processes.

To subscribe today, simply complete and submit the reply form below after reading our Emprove® terms and conditions.

References

1.
Sept. 2019. Raw Material Risk Assessments – A Holistic Approach to Raw Material Risk Assessments through Industrial Collaboration. BioPhorum.
2.
Dec. 2018. Management and Control of Raw Materials Used in the Manufacture of Biological Medicinal Products and ATMPs. European Biopharmaceutical Enterprises.
Sign In To Continue

To continue reading please sign in or create an account.

Don't Have An Account?